FDA Approves Inovio Pharmaceuticals' Voceryq for Rare Throat Disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Inovio Pharmaceuticals' INO-3107, branded as Voceryq, for the treatment of recurrent respiratory papillomatosis (RRP) in adults. This plasmid DNA-based immunotherapy is designed to reduce the frequency of surgical papilloma excisions, which are often required for this rare disease caused primarily by HPV-6 and/or HPV-11. This marks Inovio's first approved product.